SEC Form 4 · accession 0000899243-16-027468
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Regnante
Officer — Chief Financial Officer
Period of report
Aug 16, 2016
Accepted (ET)
Aug 17, 2016 · 6:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F1 | $20.89 | Aug 16, 2016 | A | 120,000 | A | — | Aug 16, 2026 | Ordinary Shares | 120,000 | 120,000 | D |
Explanation of responses
- F1The option vests as to 25% of the shares on August 16, 2017 and vests as to an additional 2.0833% of the shares monthly thereafter until August 16, 2020.